Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Feb 21, 2009; 15(7): 871-876
Published online Feb 21, 2009. doi: 10.3748/wjg.15.871
Published online Feb 21, 2009. doi: 10.3748/wjg.15.871
Table 2 Prognostic single factor analysis of ESCC
Prognostic factor | Number | Survival rate (%) | MST (mo) | P | |
1-yr | 2-yr | ||||
Sex | 0.713 | ||||
Male | 42 | 38.1 | 7.1 | 10.0 | |
Female | 119 | 26.3 | 10.5 | 8.5 | |
Age (Yr) | 0.887 | ||||
< 60 | 26 | 30.8 | 11.5 | 9.0 | |
≥ 60 | 35 | 42.9 | 5.7 | 10.0 | |
KPS | < 0.001 | ||||
60-80 | 40 | 22.5 | 0.0 | 8.0 | |
90-100 | 21 | 66.7 | 23.8 | 13.5 | |
Metastasis | < 0.001 | ||||
Mono-site | 40 | 52.5 | 12.5 | 12.5 | |
Poly-site | 21 | 9.5 | 0.0 | 6.5 | |
Prechemotherapy | 0.969 | ||||
Yes | 27 | 40.7 | 3.7 | 10.0 | |
No | 34 | 35.3 | 11.8 | 9.0 | |
Therapeutic effect | |||||
PR | 27 | 63.0 | 18.5 | 13.0 | |
SD | 24 | 25.0 | 0.0 | 9.0 | |
PD | 10 | 0.0 | 0.0 | 6.0 |
- Citation: Qin TJ, An GL, Zhao XH, Tian F, Li XH, Lian JW, Pan BR, Gu SZ. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol 2009; 15(7): 871-876
- URL: https://www.wjgnet.com/1007-9327/full/v15/i7/871.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.871